文献速递白血病

基于定量实时聚合酶链反应的预测统计模型快速识别BCR/ABL1样急性淋巴细胞白血病患者:临床、预后和治疗意义

Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.
PubMed 文献 · Br J Haematol · 2018-04-19

该研究利用基因表达谱筛选出10个在BCR/ABL1样急性淋巴细胞白血病中过表达的基因,通过定量实时聚合酶链反应在26例BCR/ABL1样和26例非BCR/ABL1样病例中建立统计预测模型,并在142例B系急性淋巴细胞白血病患者中筛查出28例(19.7%)BCR/ABL1样病例,这些病例富集JAK/STAT突变、IKZF1缺失及细胞因子受体和酪氨酸激酶重排,完全缓解率更低且无事件生存更差,原代细胞体外对帕纳替尼有反应。

要点

  • 基于10个基因的定量实时聚合酶链反应统计模型可快速识别BCR/ABL1样急性淋巴细胞白血病。
  • 筛查142例B系急性淋巴细胞白血病患者,识别出28例(19.7%)BCR/ABL1样病例。
  • BCR/ABL1样病例完全缓解率更低(P=0.014)、无事件生存更差(P=0.0009)。

核心结论

  • 作者提出一种基于定量实时聚合酶链反应和统计模型的简单工具,可在诊断时简便、快速、可靠地识别BCR/ABL1样急性淋巴细胞白血病病例。

研究设计与样本

  • 利用基因表达谱识别10个BCR/ABL1样急性淋巴细胞白血病特异性过表达基因,在26例BCR/ABL1样和26例非BCR/ABL1样病例中通过定量实时聚合酶链反应评估表达值以构建统计「BCR/ABL1样预测模型」。
  • 用该预测模型筛查142例B系急性淋巴细胞白血病患者。

主要发现

  • 142例B系急性淋巴细胞白血病患者中识别出28例BCR/ABL1样病例(19.7%)。
  • BCR/ABL1样病例富集JAK/STAT突变(P<0.001)、IKZF1缺失(P<0.001)及累及细胞因子受体和酪氨酸激酶的重排(P=0.001)。
  • BCR/ABL1样病例完全缓解率低于非BCR/ABL1样急性淋巴细胞白血病(P=0.014),无事件生存差于非BCR/ABL1样急性淋巴细胞白血病(P=0.0009)。
  • BCR/ABL1样病例的原代细胞体外对帕纳替尼有反应。

关键数值与推荐

  • BCR/ABL1样预测模型基于10个基因的定量实时聚合酶链反应表达值构建。
  • 筛查142例B系急性淋巴细胞白血病患者,BCR/ABL1样病例28例(19.7%)。
  • BCR/ABL1样病例JAK/STAT突变富集P<0.001,IKZF1缺失富集P<0.001,细胞因子受体和酪氨酸激酶重排富集P=0.001。
  • BCR/ABL1样病例完全缓解率较低P=0.014,无事件生存较差P=0.0009。

临床怎么用

  • 作者提出基于定量实时聚合酶链反应和统计模型的简单工具可在诊断时简便、快速、可靠地识别BCR/ABL1样急性淋巴细胞白血病病例。
  • 原文未据此给出临床治疗推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BCR/ABL1-like acute lymphoblastic leukaemia (ALL) is a subgroup of B-lineage acute lymphoblastic leukaemia that occurs within cases without recurrent molecular rearrangements. Gene expression profiling (GEP) can identify these cases but it is expensive and not widely available. Using GEP, we identified 10 genes specifically overexpressed by BCR/ABL1-like ALL cases and used their expression values - assessed by quantitative real time-polymerase chain reaction (Q-RT-PCR) in 26 BCR/ABL1-like and 26 non-BCR/ABL1-like cases to build a statistical "BCR/ABL1-like predictor", for the identification of BCR/ABL1-like cases. By screening 142 B-lineage ALL patients with the "BCR/ABL1-like predictor", we identified 28/142 BCR/ABL1-like patients (19·7%). Overall, BCR/ABL1-like cases were enriched in JAK/STAT mutations (P < 0·001), IKZF1 deletions (P < 0·001) and rearrangements involving cytokine receptors and tyrosine kinases (P = 0·001), thus corroborating the validity of the prediction. Clinically, the BCR/ABL1-like cases identified by the BCR/ABL1-like predictor achieved a lower rate of complete remission (P = 0·014) and a worse event-free survival (P = 0·0009) compared to non-BCR/ABL1-like ALL. Consistently, primary cells from BCR/ABL1-like cases responded in vitro to ponatinib. We propose a simple tool based on Q-RT-PCR and a statistical model that is capable of easily, quickly and reliably identifying BCR/ABL1-like ALL cases at diagnosis.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chiaretti S, Messina M, Grammatico S, et al. Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. Br J Haematol. 2018. PMID: 29675955. doi:10.1111/bjh.15251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。